Evidence map›Paper›PMID 27663357›Full record

ArticleBMC cancer2016

Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers.

Yenkai Lim, Yunxia Wan, Dimitrios Vagenas, Dmitry A Ovchinnikov, Chris F L Perry, Melissa J Davis, Chamindie Punyadeera

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Disease markers · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yenkai LimThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Yunxia WanThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Dimitrios VagenasThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Dmitry A OvchinnikovAustralian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.
Chris F L PerryDepartment of Otolaryngology, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD, 4102, Australia.
Melissa J DavisDepartment of Biomedical Engineering, University of Melbourne, Parkville, Melbourne, VIC, 3010, Australia.
Chamindie PunyadeeraThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia. chamindie.punyadeera@qut.edu.au.
Queensland University of Technology · AUThe University of Queensland · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumours with a typical 5 year survival rate of <40 %. DNA methylation in tumour-suppressor genes often occurs at an early stage of tumorigenesis, hence DNA methylation can be used as an early tumour biomarker. Saliva is an ideal diagnostic medium to detect early HNSCC tumour activities due to its proximity to tumour site, non-invasiveness and ease of sampling. We test the hypothesis that the surveillance of DNA methylation in five tumour-suppressor genes (RASSF1α, p16

methodsMethylation-specific PCR (MSP) was used to determine the methylation levels of RASSF1α, p16

resultsSalivary DNA methylation levels were not affected by age. Salivary DNA methylation levels for RASSF1α, p16

conclusionsSalivary DNA tumour-suppressor methylation gene panel has the potential to detect early-stage tumours in HPV-negative HNSCC patients. HPV infection was found to deregulate the methylation levels in HPV-positive HNSCC patients. Large-scale double-blinded clinical trials are crucial before this panel can potentially be integrated into a clinical setting.

Indexed as

Cross-fold validation and early detectionDNA methylationEpigenetics biomarkersHead and neck cancersHuman PapillomavirusSalivaTumour-suppressor genes

Identifiers

PMID27663357
PMCPMC5034533
OpenAlexW2521526551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.